A novel nomogram based on DLL3 and PD-L1 for predicting the prognosis of patients with small cell lung cancer

Authors:

Abstract
Background Small cell lung cancer (SCLC) is known for its highly invasive nature and low 5-year survival rate. Although immunotherapy has shown enhancements in survival among SCLC patients, there is a call for improved precision in targeting beneficiary populations. The development of the Delta-like ligand 3 (DLL3)-targeted drug Rovalpituzumab Tesirine (Rova-T) was halted due to insufficient efficacy, prompting a closer examination of factors influencing treatment effectiveness. This study aims to create a prognostic model for SCLC patients based on protein expression levels to enhance prognosis determination and guide clinical decision-making. cal or histopathological examination from March 13, 2017 to March 12, 2022 in Changzhi People's Hospital, Shanxi were enrolled. The study had specific criteria for
Funding Information
  • Changzhi People's Hospital (202003)

This publication has 60 references indexed in Scilit: